AI biotech Fathom raises $47M Series A, renames from Atommap
In the early 2000s, way before AI became a ubiquitous buzzword in biotech, billionaire scientist David Shaw was building supercomputers to study molecules at his eponymous research company. Huafeng Xu, a longtime scientific leader at ...
From L-R: Fathom Therapeutics founder and CEO Huafeng Xu, with co-founders Yujie Wu and Jesus Izaguirre April 27, 2026 07:00 AM EDT FinancingAI Exclusive: Fathom raises $47M, blending AI and physics in drug discovery Andrew Dunn Senior Biopharma Correspondent In the early 2000s, way before AI became a ubiquitous buzzword in biotech, billionaire scientist David Shaw was building supercomputers to study molecules at his … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER
comments(0)
5-min edit window · permanent after that